Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Fig. 8

Working model of SAHA and Veliparib co-treatment. SAHA and veliparib exhibited synergistic anticancer efficacy in prostate cancer cells by two mechanisms: synergistically inducing DNA damage, and impairing DNA damage repair by reducing HR DNA repair molecule BRCA1 levels via UHRF1. Co-treatment promoted DNA damage and impaired the damaged DNA repair, and enhanced cell apoptosis and cell death

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us